Imagine a world where patients with AL amyloidosis and other immune-mediated diseases can access a one-time, transformative treatment right at their doorstep. At ImmixBio, we see a horizon where this is possible.

Based on the groundbreaking cell therapy research in the early 2010s of Dr. Carl June at University of Pennsylvania, Dr. Renier Brentjens formerly of Memorial Sloan Kettering, and others, the first cell therapies were approved in the United States in August and October 2017, Kymriah® and Yescarta® for certain types of blood cancers.

Since then, the United States has seen a blossoming of experts in the field, manufacturing sites, as well as clinical and patient experience in the cell therapy space. Despite this progress, due to neurotoxicity and other side effects, 95% of U.S. medical centers are unable to dose these pioneering CAR-T cell therapies. Additionally, also due to neurotoxicity and other side effects, only a narrow band of patients in specific indications are able to benefit from CAR-Ts.

At ImmixBio, we aim to change that paradigm by being the first company to overcome the greatest obstacle to CAR-T adoption: neurotoxicity. By overcoming neurotoxicity, we aim to expand into indications that were not possible in the past (starting with AL Amyloidosis), and places not possible in the past (the 95% of U.S. medical centers today that are unable to dose CAR-T therapies).